Literature DB >> 32386473

Postoperative fever in the time of COVID-19.

Jonathan Bourget-Murray1, Bryan J Heard1, Rohit Bansal1, Andrew S Johnson1, James Powell1.   

Abstract

Summary: Postoperative fever is common following orthopedic trauma surgery. As the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection increases in the community, migration into the acute care hospital setting intensifies, creating confusion when fever develops postoperatively. The transmission dynamics of SARS-CoV-2 make it difficult to adequately gauge and pinpoint risk groups with questionnaires at the time of hospital admission. This is particularly problematic when asymptomatic or presymptomatic patients infected with SARS-CoV-2 require urgent surgery and cannot be screened effectively. One approach is to treat every patient as though they were SARS-CoV-2-positive in preparation for surgery, but doing so could exacerbate shortages of personal protective equipment and staffing limitations. Uncertainty regarding the etiology of postoperative fever could be significantly reduced by universal SARS-CoV-2 testing of all surgical patients at the time of hospital admission in addition to routine screening, but testing capacity and a rapid turnaround time would be required.
© 2020 Joule Inc. or its licensors.

Entities:  

Mesh:

Year:  2020        PMID: 32386473     DOI: 10.1503/cjs.004720

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  2 in total

1.  Medical research during a pandemic.

Authors:  Chad G Ball; Edward J Harvey
Journal:  Can J Surg       Date:  2020-06-04       Impact factor: 2.089

2.  Reduction in the Duration of Postoperative Fever during the COVID-19 Pandemic in Orthopedic and Traumatic Surgery Due to PPE and Cautions.

Authors:  Pierluigi Mastri; Francesco Di Petrillo; Alessandro Cerone; Mario Muselli; Michela Saracco; Giandomenico Logroscino; Vittorio Calvisi
Journal:  J Clin Med       Date:  2022-03-16       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.